These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38783951)

  • 1. Assessing the safety of bedaquiline: insight from adverse event reporting system analysis.
    Wu J; Pan H; Shen L; Zhao M
    Front Pharmacol; 2024; 15():1382441. PubMed ID: 38783951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
    Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
    J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Jun; ():. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system.
    Xia C; Liu Z; Liu J; Lin L; Chen M
    Invest New Drugs; 2024 Aug; ():. PubMed ID: 39133357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 7. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.
    Dai Z; Wang G; Zhang J; Zhao Q; Jiang L
    Heliyon; 2024 Jul; 10(13):e33417. PubMed ID: 39027557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
    Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system.
    Chang E; Shi YF; Liu JF; Wei W
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38700323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The real-world safety of oseltamivir and baloxavir marboxil in children: a disproportionality analysis of the FDA adverse event reporting system.
    Wei W; Huang L; Bai Y; Chang E; Liu J
    Front Pharmacol; 2024; 15():1391003. PubMed ID: 39050747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver injury due to endothelin receptor antagonists: a real-world study based on post-marketing drug monitoring data.
    Dong S; Guo X; Wang H; Sun C
    Ther Adv Respir Dis; 2024; 18():17534666231223606. PubMed ID: 38179676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.
    Li S; Huang R; Meng Y; Liu Y; Qian J; Zou J; Yang J
    Front Pharmacol; 2024; 15():1420126. PubMed ID: 39161895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
    Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
    Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
    [No Abstract]   [Full Text] [Related]  

  • 14. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
    Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
    [No Abstract]   [Full Text] [Related]  

  • 15. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.
    Zhang X; Ren X; Zhu T; Zheng W; Shen C; Lu C
    Front Pharmacol; 2024; 15():1407709. PubMed ID: 39114350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
    Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
    Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
    [No Abstract]   [Full Text] [Related]  

  • 17. Signal mining and analysis of trifluridine/tipiracil adverse events based on real-world data from the FAERS database.
    Hu Y; Du Y; Qiu Z; Zhu C; Wang J; Liang T; Liu T; Da M
    Front Pharmacol; 2024; 15():1399998. PubMed ID: 39108741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-Marketing Safety Concerns with Upadacitinib: A Disproportionality Analysis of the FDA Adverse Event Reporting system.
    Wu XP; Lu XK; Wang ZT; Huang L; Cai RW; Yu HM; Li JY; Xiao J
    Expert Opin Drug Saf; 2023; 22(10):975-984. PubMed ID: 37310063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.